NCT07250347 AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT
| NCT ID | NCT07250347 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Condition | Gastric Cancer Stage |
| Study Type | OBSERVATIONAL |
| Enrollment | 8,000 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2028-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 8,000 participants in total. It began in 2025-08-01 with a primary completion date of 2028-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Accurate preoperative assessment of gastric cancer stage guides eligibility for endoscopic resection, extent of gastrectomy and lymphadenectomy, selection for neoadjuvant therapy, and use of staging laparoscopy. Contrast-enhanced CT (CECT) is guideline-endorsed for initial staging, yet performance varies across institutions and readers. This study will evaluate an artificial-intelligence (AI) system that analyzes routine CECT to detect gastric cancer and assign four-class T stage (T1-T4) and N stage (N0-N3) .
Eligibility Criteria
Inclusion Criteria: 1. pathologically confirmed gastric cancer; 2. preoperative contrast-enhanced CT performed; 3. no evidence of distant metastasis on baseline staging; 4. curative-intent management with complete postoperative histopathology. Exclusion Criteria: 1. prior treatment before surgery; 2. non-diagnostic or poor-quality CT precluding evaluation.
Contact & Investigator
Zhang Yudong
PRINCIPAL INVESTIGATOR
The First Affiliated Hospital with Nanjing Medical University
Frequently Asked Questions
Who can join the NCT07250347 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Gastric Cancer Stage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07250347 currently recruiting?
Yes, NCT07250347 is actively recruiting participants. Contact the research team at zhangyd3895@njmu.edu.cn for enrollment information.
Where is the NCT07250347 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT07250347 clinical trial?
NCT07250347 is sponsored by The First Affiliated Hospital with Nanjing Medical University. The principal investigator is Zhang Yudong at The First Affiliated Hospital with Nanjing Medical University. The trial plans to enroll 8,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.